Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $117.2 million.

  • Ultragenyx Pharmaceutical's Cash from Investing Activities rose 14253.4% to $117.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.0 million, marking a year-over-year increase of 28063.55%. This contributed to the annual value of -$17.8 million for FY2024, which is 11057.62% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Cash from Investing Activities is $117.2 million, which was up 14253.4% from $71.2 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Cash from Investing Activities high stood at $119.9 million for Q1 2025, and its period low was -$275.5 million during Q3 2024.
  • Its 5-year average for Cash from Investing Activities is -$1.5 million, with a median of $64.3 million in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 39790.7% in 2023, then tumbled by 52849.68% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Cash from Investing Activities stood at $69.1 million in 2021, then crashed by 348.49% to -$171.6 million in 2022, then surged by 37.64% to -$107.0 million in 2023, then soared by 196.0% to $102.7 million in 2024, then rose by 14.06% to $117.2 million in 2025.
  • Its last three reported values are $117.2 million in Q3 2025, $71.2 million for Q2 2025, and $119.9 million during Q1 2025.